Energetic Immune Cells are Vital for Fighting Disease
News Mar 07, 2015
A good immune system relies on a key ‘energy producing’ protein in immune cells to develop immunity to vaccines and disease, an international team of scientists has found.
The protein, called HuR (human antigen R) is critical for controlling metabolism in B cells, which make antibodies that are essential in fighting infections and in developing long-term immunity after vaccination.
Dr Kirsten Fairfax, now at Melbourne’s Walter and Eliza Hall Institute, worked with Dr Manuel Diaz-Muñoz, Dr Martin Turner and colleagues at the Babraham Institute, Cambridge, UK, on the discovery, published in the journal Nature Immunology.
Dr Fairfax said the team showed removing HuR prevented the proper growth and function of B cells. “Immune cells called B cells mature in response to vaccines or exposure to new disease and are a key tenet of immunity,” she said. “HuR ‘manages’ a set of genes that determine how much energy B cells produce, known as the metabolic rate.
“We showed that without HuR to instruct them, these critical metabolic genes can no longer instruct the B cell to make the energy it needs to function, and B cells are unable to mature into antibody-producing cells that provide immunity to disease.”
Powering the 'B cell factory'
This final stage of maturation requires a substantial amount of energy and occurs in a ‘B-cell factory’ called the germinal centre, Dr Fairfax said. “Germinal centres are the quality control check point for B cells,” she said. “B cells that pass the test mature and transform into antibody-producing (plasma) cells, while those that fail quality control start the maturation process again.
“If the immune cell’s metabolism isn’t functioning properly, maturation in the germinal centre stalls and plasma B cells cannot develop,” she said. This is potentially disastrous for the immune system as plasma B cells protect the body from infections and generate immunity after vaccination to prepare for future infections.”
Understanding the processes that control B cell development, including metabolism, can help scientists find ways to boost the efficacy of vaccines or preserve the body’s ability to develop immunity.
“As an example, some anti-cancer drugs that are used over extended treatment periods can impact cell metabolism,” Dr Fairfax said. “If these drugs impact on the metabolism of B cells, it may compromise a patient’s ability to create the new plasma B cells required to prevent infections. Identifying which drugs have this impact and monitoring patients receiving these drugs will help clinicians guide cancer patients through treatment while ensuring efforts to restore their immune system are effective.
The research was supported by the Australian National Health and Medical Research Council, the Biotechnology and Biological Sciences Research Council (UK) and the Victorian Government.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.